Cite
Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS
MLA
Butzkueven, H., et al. Efficacy and Treatment Persistence of First-Line Natalizumab vs. Interferon Beta or Glatiramer Acetate in Relapsing MS. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..81d216a6faa4f815cd1e51cca15e772d&authtype=sso&custid=ns315887. Accessed 20 Sept. 2024.
APA
Butzkueven, H., Spelman, T., Kalincik, T., Jokubaitis, V., Zhang, A., Pellegrini, F., Wiendl, H., Belachew, S., Hyde, R., Verheul, F., Lugaresi, A., Havrdova, E., Horakova, D., Grammond, P., Duquette, P., Prat, A., Iuliano, G., Terzi, M., Izquierdo, G., … Top, I. (n.d.). Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.
Chicago
Butzkueven, H., T. Spelman, T. Kalincik, V. Jokubaitis, A. Zhang, F. Pellegrini, H. Wiendl, et al. 2024. “Efficacy and Treatment Persistence of First-Line Natalizumab vs. Interferon Beta or Glatiramer Acetate in Relapsing MS.” Accessed September 20. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..81d216a6faa4f815cd1e51cca15e772d&authtype=sso&custid=ns315887.